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The forkhead box (FOX) M1 transcription factor is required to maintain the proliferation of
cancer cells. Two transcriptionally active isoforms of FOXM1, FOXM1b and FOXM1c, have
been identiﬁed, but their functional differences remain unclear. FOXM1c is distinguished
from FOXM1b by an extra exon (exon Va) that contains an ERK1/2 target sequence. Based
on a literature search and quantitative PCR analysis, we concluded that FOXM1b is the
predominant isoform that is overexpressed in cancers. The further characterization of
FOXM1b and FOXM1c revealed two interesting differences. First, FOXM1b exhibited a
higher transforming ability than FOXM1c in a soft agar assay. Second, the transactivating
activity of FOXM1c, but not that of FOXM1b, was sensitive to activation byRAF/MEK/MAPK
signaling. Importantly, the MEK1 activation of FOXM1c was associated with proteolytic
processing to generate short forms thatmight represent constitutively active formsmissing
the N-terminal inhibitory domain; in contrast, the proteolytic processing of FOXM1b did not
require MEK1 activation. Our ﬁndings suggest that FOXM1b is functionally more active.
These results provide novel insights into the regulation of FOXM1 activity and its role in
tumorigenesis.
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INTRODUCTION
Forkhead box (Fox) M1 is a proliferation-speciﬁc transcription
factor that is ubiquitously expressed in embryonic tissues and cul-
tured cells (Wierstra and Alves, 2007; Kalin et al., 2011). FoxM1
knockout mice died in utero between E13.5 and E16.5, and the
developing liver andheart exhibit structural abnormalities (Korver
et al., 1998; Krupczak-Hollis et al., 2004). Cells with enlarged poly-
ploid nuclei were found in the abnormal tissues, providing the ﬁrst
indication that FoxM1 function may be required for the proper
coupling of the S and M phases of the cell cycle. Importantly,
FoxM1−/− MEFs and FOXM1-depleted cancer cells have dif-
ﬁculty undergoing mitosis and exhibit chromosomal instability
and polyploidy (Laoukili et al., 2005; Wang et al., 2005; Wonsey
and Follettie, 2005). Microarray, chromatin immunoprecipita-
tion (ChIP), and more recently, ChIP-seq analyses have identiﬁed
importantG2/M-speciﬁc genes, such as cyclinB1,Cdc25B,CenpA,
and Aurora B, as direct targets of FoxM1 (Laoukili et al., 2005;
Wang et al., 2005; Wonsey and Follettie, 2005; Chen et al., 2012).
These ﬁndings support the hypothesis that FoxM1 plays a critical
role in mitosis.
Considering the critical role of FOXM1 in promoting mitosis,
it is not surprising that the level of this protein is upregulated
in various human cancers. Indeed, the depletion of FoxM1 in
various mouse models suppresses cell division and thus tumor
formation (Wierstra and Alves, 2007; Kalin et al., 2011). Although
FoxM1 expression is initiated before S phase entry, its transcrip-
tional activity is suppressed until the G2/Mphase when the FoxM1
protein becomes highly phosphorylated (Korver et al., 1997; Leung
et al., 2001; Laoukili et al., 2007). FoxM1 phosphorylation is
promoted by mitogenic signals. In cancer cells, which are usu-
ally subjected to enhanced mitogenic signals, elevated FOXM1
levels were found to promote the G1/S transition and to sup-
press senescence (Wang et al., 2008; Anders et al., 2011). FOXM1
upregulation was also shown to promote cancer initiation and
maintenance by inducing genomic instability (Gemenetzidis et al.,
2009, 2010; Teh, 2012). In gliomas, FOXM1 was recently shown
to interact with β-catenin to promote the nuclear translocation of
β-catenin to activate the expression ofWNT target genes in glioma
stem cells, leading to their self-renewal and tumorigenesis (Zhang
et al., 2011).
The various effects of FOXM1 are thought to be mediated
by two transcriptionally active isoforms, FOXM1b and FOXM1c
(Wierstra and Alves, 2007). The only difference between FOXM1c
andFOXM1b is the presence of exonVa,which contains anERK1/2
target sequence, in the c isoform (Ma et al., 2005). In addition to
exon Va, the transcriptionally inactive isoform FOXM1a contains
exon VIIa, which confers an inhibitory effect on transcription.
RT-PCR and RNase protection analyses indicate that FOXM1c
is ubiquitously expressed in various primary and secondary cell
lines and in neonatal tissues rich inmitotically active cells, whereas
FOXM1b is themajor isoform expressed in the skin and testes (Yao
et al., 1997; Teh et al., 2002; Ma et al., 2005). The analysis of the
more ubiquitous c isoform in cultured cells byWierstra and Alves
(2006a,c) demonstrated that FOXM1c is kept inactive by internal
inhibitory domains and by RB binding. However, most overex-
pression analyses in animal models have been performed using
FOXM1b (Kalin et al., 2011). Hitherto, the parallel comparison of
FOXM1c and FOXM1b function in either cell or animal models
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has not been performed, apart from the early studies showing
that both isoforms are transcriptionally active in transient reporter
assays (Ye et al., 1997; Leung et al., 2001). The a isoform is not con-
served inmouse and its physiological signiﬁcance remains unclear
(Ma et al., 2005).
FOXM1B, THE ISOFORM UPREGULATED IN CANCER CELLS,
HAS A HIGHER TRANSFORMING POTENTIAL
Analyses of FOXM1 expression in tumor samples of diverse ori-
gins have consistently demonstrated a tight correlation between
FOXM1 upregulation and enhanced tumorigenic potential but
most studies have not addressed whether FOXM1b and FOXM1c
are differentially regulated. After reviewing PubMed articles iden-
tiﬁed using FOXM1 as a keyword, we identiﬁed eight studies in
which the FOXM1b and FOXM1c transcript levels were distin-
guished by RT-PCR or qPCR analyses (Teh et al., 2002, 2012; Liu
et al., 2006; Gemenetzidis et al., 2009;Nakamura et al., 2010; Zhang
et al., 2011; Dibb et al., 2012; Newick et al., 2012). In these studies,
FOXM1b was reported to be the predominant isoform overex-
pressed in cancer cells, whereas FOXM1c is ubiquitously expressed
in both normal and cancer cells. To validate this result, we sub-
jected three human primary cell lines [HDFs (skin), HUVECs
(blood vessel), and IMR-90 cells (lung)] and ﬁve cancer cell lines
[A549 (lung), MDA-MB-231 (breast), HeLa (cervix), A2780CP
(ovary), andHL-60 (blood)] to RT-PCR and real-time qPCR anal-
yses. As shown in Figure 1A, using primers ﬂanking exon Va, the
b-speciﬁc product of 323 bp was detectable in the cancer cell lines
but not in the primary cell lines, whereas all samples showed the
368 bp c- or a-speciﬁc fragment.Withmore sensitive qPCR assays,
two TaqMan probes (from ABI) that detect the b-speciﬁc and
non-b (i.e., FOXM1a and FOXM1c) transcripts, respectively, were
employed. When compared with the levels in HUVECs, the lev-
els of FOXM1b mRNA remained low in the primary cell lines but
increased by 5.5-fold (e.g.,A549) to 95-fold (HL-60) in cancer cells
(Figure 1A). In contrast, the levels of the FOXM1a and FOXM1c
transcripts did not increase much in the cancer cell lines. If the
increased levels of the b isoform in cancer cells were solely due
to changes in proliferative potential and conditions of culturing,
we would expect corresponding changes of all isoforms. However,
the varying extent of increases in FOXM1c levels in the different
cancer cell lines may partially reﬂect a cell/tissue type effect and
extensive analysis of more cell lines of different tissues would be
required to distinguish cell or tissue type speciﬁc effect. As a ﬁrst
attempt to determine whether the b isoform, the level of which is
elevated in cancer cells, has a transforming potential similar to that
of the c isoform, we ectopically expressed FOXM1b or FOXM1c
in A2780CP cells and performed a soft agar colony-forming assay.
FOXM1b exhibited a transforming potential 10-fold greater than
that of FOXM1c (Figure 1B).
FOXM1C, BUT NOT FOXM1B, IS ACTIVATED BY
RAF/MEK/MAPK SIGNALING
While investigating the regulation of FOXM1 function by
RAF/MEK/MAPK signaling, we noted another interesting dif-
ference between the b and c isoforms (Ma et al., 2005). When a
constitutively active form of MEK1 (caMEK1) was coexpressed
with either FOXM1c or FOXM1b and the cyclin B1 reporter in
transient assays, only FOXM1c showed a signiﬁcant enhancement
of transactivating activity. The enhancing effect was lost when a
dominant negative form of MEK1 (dnMEK1) was coexpressed.
To explore the biochemical basis of the differential responsive-
ness of the two isoforms, a FOXM1c or FOXM1b construct,
tagged at the C-terminus with a V5 tag, was cotransfected with
or without MEK1 (caMEK1 or dnMEK1) into HEK293 cells,
and the cell lysates subjected to immunoblot analysis using an
anti-V5 antibody (Figure 2). Interestingly, the stimulation of
RAF/MEK/MAPK signaling was found to promote the prote-
olytic processing of FOXM1c to generate multiple short forms
(Figure 2A). One truncated form(indicatedby an arrow)migrated
with similar mobility as the Del-N form of FOXM1c (artiﬁcially
generated by the deletion of the N-terminal 187 amino acids).
Missing the N-terminal inhibitory domain (Luscher-Firzlaff et al.,
2006; Wierstra and Alves, 2006a,b), the Del-N form has long
been known to exhibit greatly enhanced transcriptional activ-
ity. The proteolytic processing of FOXM1c was suppressed with
the coexpression of dnMEK1. However, the proteolytic pro-
cessing of FOXM1b appeared constitutive and was unaffected
by the activation or inhibition of RAF/MEK/MAPK signaling
(Figure 2A). To conﬁrm this differential regulation of the two iso-
forms by RAF/MEK/MAPK signaling, we also subjected FOXM1c-
or FOXM1b-transfected HEK293 cells to treatment with media
containing different amounts of serum. As shown in Figure 2B,
increases in the serum concentration and therefore in the level of
activation of RAF/MEK/MAPK signaling led to the increased pro-
cessing of FOXM1c, whereas the level of FOXM1b processing was
independent of the serum content.
CONCLUSION AND PERSPECTIVES
In this article, we presented evidence to support the hypothesis
that the b isoform, which is frequently overexpressed in can-
cers, represents a more active form of FOXM1. In contrast, the
ubiquitously expressed c isoform is a greatly attenuated form of
FOXM1 that requires activation by RAF/MEK/MAPK signaling.
It has long been known that FOXM1 is an M phase phosphopro-
tein and that its phosphorylation is associated with proteolytic
processing (Westendorf et al., 1994; Korver et al., 1997) to gener-
ate shorter forms of FOXM1. However, it remains unclear whether
any of theN-terminal truncated forms,which resembles theDel-N
formmissing theN-terminal inhibitory domain, represent physio-
logically functional forms of FOXM1. Phosphorylation by various
cyclin/Cdks has previously been shown to relieve the autorepres-
sion of FOXM1 by the N-terminal inhibitory domain (Wierstra
and Alves, 2006b; Laoukili et al., 2008; Park et al., 2008). Mass
spectrometry and further biochemical analyses would be required
to determine whether MAPK-activated proteolytic cleavage may
represent another regulatory mechanism.
FOXM1c is negatively regulated by RB binding, and the 15-
amino-acid domain encoded by exonVa (missing in the b isoform)
is within the RB-binding domain. It remains to be tested whether
FOXM1b binds with lower afﬁnity to RB and is therefore less
repressed. This reduced level of repression might explain why
FOXM1b is constitutively processed, whereas FOXM1c might
be protected by RB binding. Further, it would be interesting to
explore how splicing is regulated in cancer cells to favor increased
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FIGURE 1 | FOXM1b has higher expression levels and transforming
potential in cancer cells. (A) FOXM1 mRNA levels of three primary and
ﬁve cancer cell lines were determined by RT-PCR and real-time qPCR
analyses. Using primers ﬂanking exon Va, RT-PCR analysis led to the
ampliﬁcation of 323 and 368-bp products for FOXM1b and non-FOXM1b (i.e.,
FOXM1a and FOXM1c) transcripts, respectively. For real-time qPCR analysis,
predesigned ABI TaqMan probes for FOXM1b (assay ID: Hs01080645_m1)
and FOXM1a/c (assay ID: Hs01073587_m1) transcripts were used to
determine their levels against glyceraldehyde 3-phosphate dehydrogenase
(GAPDH) transcripts. Relative FOXM1 expression levels are shown as
mean ± SE, with the HUVEC level set as 1.00. (B) Soft agar colony-forming
assay performed using A2780CP cells revealed that the transforming
potential of FOXM1b is 10-fold greater than that of FOXM1c.
*P = 0.0064.
FIGURE 2 | RAF/MEK/MAPK signaling stimulates the proteolytic
processing of FOXM1c. (A) HEK293 cells were cotransfected with
V5-tagged FOXM1c (V5-c) or FOXM1b (V5-b) cDNA in the presence or
absence of dominant negative (dn) or constitutively active (ca) MEK1
cDNA. Immunoblot analysis using an anti-V5 antibody revealed that
proteolytic processing of FOXM1c is enhanced with activated
RAF/MEK/MAPK signaling. The arrow indicates a truncated form of
V5-tagged FOXM1 that migrated with similar mobility as the Del-N
form of FOXM1c. The proteolytic processing of FOXM1b appears
constitutive and is unaffected by RAF/MEK/MAPK signaling. (B) V5-tagged
FOXM1c- or FOXM1b-transfected HEK293 cells were subjected to treatment
with medium containing different amounts of serum for 48 h before their
harvest for immunoblot analysis. The proteolytic processing of FOXM1c is
enhanced with increases in the serum concentration whereas FOXM1b
processing is constitutive and is unaffected by changes in serum
concentration.
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FOXM1b synthesis. Furthermore, the targeted deletion of exon
Va in mice would reveal whether the constitutive expression of
FoxM1b will increase the susceptibility of these mice to cancer.
The forced expression of FoxM1c by the targeted deletion of the
introns ﬂanking exonVamight affect spermatogenesis because the
b isoform is highly expressed in the testes, but these mice might be
less susceptible to cancer.
In summary, we argue that the further study of the functional
and regulatory differences between the b and c isoforms is essen-
tial before the therapeutic targeting of FOXM1 in cancer cells can
be effective. Further analysis is also necessary to explore the pos-
sibility that the targeted activation of FOXM1 expression could
be used to enhance cell regeneration without causing cancer. It is
worth noting that FoxM1has recently been shown to regulateOct4
expression and that its function is required for the maintenance of
pluripotency in stem cells (Xie et al., 2010). In addition, FoxM1has
been shown to be an effector of DNA damage response by upreg-
ulating the expression of antioxidant genes (Tan et al., 2007; Park
et al., 2009). We believe that the positive side of FOXM1 function
remains to be exploited.
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